Phase II DMD Trailhead data hike Satellos’ stock
· randy osborne
AI Briefing
- • Satellos Bioscience Inc. may seek accelerated approval for SAT-3247 in Duchenne muscular dystrophy.
- • SAT-3247 showed positive results in the adult phase II Trailhead study.
- • Shares rose 9.4% to $8.98 after interim data was made public.
Source Summary
Pending talks with regulators, Satellos Bioscience Inc. may seek accelerated approval in Duchenne muscular dystrophy (DMD) for SAT-3247, which yielded positive results in the adult phase II Trailhead study. Shares of Toronto-based Satellos (NASDAQ:MSLE) closed July 8 at $8.98, up 77 cents, or 9.4%, after the firm made public six-month interim data from Trailhead.
Advertisement